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Summary We performed a phase I and pharmacological study to determine the maximum tolerated dose (MTD) and dose-limiting toxicities
(DLT) of a cytotoxic regimen ofthe novel topoisomerase I inhibitortopotecan in combination with thetopoisomerase 11 inhibitoretoposide, and
to investigate the clinical pharmacology of both compounds. Patients with advanced solid tumours were treated at 4-weekintervals, receiving
topotecan intravenously over 30 min on days 1-5 followed by etoposide given orally twice daily on days 6-12. Topotecan-etoposide dose
levels were escalated from 0.5/20 to 1.0/20, 1.0/40, and 1.25/40 (mg m-2 day-')/(mg bid). After encountering DLT, additional patients were
treated at 3-week intervals with the topotecan dose decreased by one level to 1.0 mg m-2 and etoposide administration prolonged from 7 to
10 days to allow further dose intensification. Of 30 patients entered, 29 were assessable for toxicity in the first course and 24 for response.
The DLT was neutropenia. At doses of topotecan-etoposide 1.25/40 (mg m-2)/(mg bid) two out of six patients developed neutropenia grade
IV that lasted more than 7 days. Reduction of the treatment interval to 3 weeks and prolonging etoposide dosing to 10 days did not permit
further dose intensification, as a time delay to retreatment owing to unrecovered bone marrow rapidly emerged as the DLT. Post-infusion total
plasma levels of topotecan declined in a biphasic manner with a terminal half-life of 2.1 ± 0.3 h. Total body clearance was 13.8 ± 2.71 h-1 m-2
with a steady-state volume of distribution of 36.7 ± 6.2 m-2. N-desmethyltopotecan, a metabolite oftopotecan, was detectable in plasma and
urine. Mean maximal concentrations ranged from 0.23 to 0.53 nmol 1-1, and were reached at 3.4 ± 1.0 h after infusion. Maximal etoposide
plasma concentrations of 0.75 ± 0.54 and 1.23 ± 0.57gmol 1-1 were reached at 2.4 ± 1.2 and 2.3 ± 1.0 h after ingestion of 20 and 40 mg
respectively. The topotecan area underthe plasma concentration vs time curve (AUC) correlated with the percentage decrease in white blood
cells (WBC) (r2 = 0.70) and absolute neutrophil count (ANC) (tQ = 0.65). A partial response was observed in a patient with metastatic ovarian
carcinoma. A total of 64% of the patients had stable disease for at least 4 months. The recommended dose for use in phase 11 clinical trials is
topotecan 1.0 mg m-2 on days 1-5 and etoposide 40 mg bid on days 6-12 every 4 weeks.
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Since the recent recognition ofDNA topoisomerases as the cellular
target of a number of clinically important anti-cancer drugs,
including anthracyclines, epipodophyllotoxins and the upcoming
class of camptothecins, these enzymes have become the focus of
intensive preclinical and clinical research (D'Arpa et al, 1989;
Cummings et al, 1993; Pommier et al, 1993). Topoisomerases are
essential nuclear enzymes that alter the topology of DNA during
DNA metabolism by cleavage ofDNA strands, strand passage and
religation (Wang, 1985). Two majortopoisomerases, types I and H,
have been identified in all mammalian cells, and induce single-
and double-strand breaks respectively. Topoisomerase I and II
inhibitors poison these enzymes by stabilizing the transient
enzyme-DNA cleavable complex, which can result in DNA strand
breakage and finally cell death. Although they are inhibitors of
similar enzymes, the two classes of agents kill cells in a quite
different manner. They have different sites of binding DNA and
play a different role in the cell cycle.
Received 15 November 1996
Revised 19 February 1997
Accepted 10April 1997
Correspondence to: VMM Herben, Slotervaart Hospital, Department of
Pharmacy and Pharmacology, Louwesweg 6, 1066 EC Amsterdam,
The Netherlands
Topotecan (Hycamtin), a semisynthetic water-soluble derivative
of camptothecin, was the first topoisomerase I-targeting drug to
undergo clinical testing since the discontinuation of the clinical
development of sodium camptothecin in the early 1970s.
Currently, topotecan is one of the most promising novel antineo-
plastic agents for the treatment of solid tumours, with demon-
strated activity in ovarian cancer (Armstrong et al, 1995), breast
cancer (Chang et al, 1995) and small-cell lung cancer (Ardizzoni
et al, 1995). In view of topotecan's unique mechanism of action
and important anti-tumour effects as single agent, recent studies
have focused on combination therapies with other effective anti-
cancer agents.
The combination of topoisomerase I inhibitors with topoiso-
merase II poisons is in theory an attractive strategy. As resistance
to inhibition of one class of topoisomerase enzymes is accompa-
nied with an elevated sensitivity to the other class of topoiso-
merase inhibitors in vitro (Tan et al, 1989; Sugimoto et al, 1990), a
combined administration regimen of inhibitors of both topoiso-
merases could effectively kill tumour cells. The advantage of this
combination over single-agent administration appears to be
schedule dependent. Significant synergy in vitro and in vivo has
been demonstrated to occur with topoisomerase II inhibitors given
after a 24-48-h drug-free interval after treatment with a topoiso-
merase I inhibitor (Kozelsky et al, 1995; Masumoto et al, 1995),
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Table I Dose levels
Relative dose intensitya
Dose level Topotecan (mg m-2 day x 5) Etoposide (mg bid x 7) Treatment interval (days) Topotecan Etoposide Average
1 0.5 20 28 0.25 0.13 0.19
2 1.0 20 28 0.50 0.13 0.32
3 1.0 40 28 0.50 0.27 0.38
4 1.25 40 28 0.63 0.27 0.45
3a 1.0 40 x 10 days 21 0.67 0.51 0.57
2a 1.0 20 x 10 days 21 0.67 0.25 0.46
aRelative dose intensity is the amount of drug delivered per unit of time in the test regimen relative to the standard single drug regimen, or for a combination
regiment the decimal fraction of the ratio of the average dose intensity of all drugs in the combination regimen compared with the standard regimen (DeVita,
1993). In the calculations, regimens of topotecan of 1.5 mg m-2 day-' days 1-5 every 21 days, and etoposide 100 mg day-' days 1-21 every 28 days were
assumed to be standard single drug regimens.
whereas the anti-cancer effect was attenuated when topoisomerase
II poisons were administered concurrently or immediately after
topoisomerase inhibition (D'Arpa et al, 1990; Kaufmann, 1991;
Bertrand et al, 1992; Kim et al, 1992).
These data led us to evaluate a chemotherapeutic regimen of
topotecan in combination with etoposide, a representative
inhibitor of topoisomerase II. We initiated a phase I and pharma-
cological study with topotecan and etoposide combined in a
schedule that hypothetically maximizes the likelihood of
producing synergistic effects while diminishing the likelihood of
inhibitory effects, i.e. etoposide dosing preceded by topotecan
infusion. Preclinical and clinical data indicate enhanced antineo-
plastic activity when topotecan is administered daily forprolonged
periods of time. Most clinical responses were observed with a
daily 30-min times five infusion schedule. The recommended dose
for this schedule is 1.5 mg m-2 day-1 (Rowinsky et al, 1991;
Verweij et al, 1993). Etoposide also exerts schedule dependency,
with the greatest activity seen after prolonged exposure. As
chronic infusion is cumbersome and expensive and anti-tumour
activity is retained with repeated low administration forprolonged
periods, an oral 'low-dose' formulation containing 20 mg of
etoposide was developed in our hospital pharmacy (Jonkman-De
Vries et al, 1996). The objectives ofthis phase I study were (a) to
determine the maximum-tolerated doses for the combination of
daily 30-min infusions of topotecan on days 1-5 followed by oral
etoposide on days 6-12, (b) to characterize the dose-limiting
toxicities associated with this regimen, and (c) to investigate the
clinical pharmacology oftopotecan and etoposide.
PATIENTS AND METHODS
Patient population
Patients were eligible if they had a histologically confirmed diag-
nosis of a solid malignant tumour that was not amenable to estab-
lished forms ofeffective therapy. Other eligibility criteria included
a Zubrod-ECOG-WHO performance status < 2, anticipated life
expectancy of2 3 months and age 2 18 years. Previous anti-cancer
chemotherapy had to be discontinued for at least 4 weeks before
entry into the study or 6 weeks in cases of pretreatment with a
nitrosourea or mitomycin C. All patients had acceptable bone
marrow function white blood cell (WBC) .4 x 109 1-1 and
platelets 2 100 x 109 11; normal hepatic function, serum bilirubin
< 1.5 mg dl-' (25 pmol 1-1) and otherliver function tests < twice the
normal upper limit or < five times when related to liver metastases,
prothrombin or thrombotest within normal limits; normal renal
function, serum creatinine < 1.4 mg dl-1 (120 gmol 1-1). The study
protocol was approved by the Medical Ethics Committee of the
hospital, and all patients gave written informed consent.
Treatment plan and study design
Topotecan (SmithKline Beecham Pharmaceuticals, King of
Prussia, PA, USA) was supplied by the National Cancer Institute
as a lyophilized light yellow powder in vials containing 5 mg of
topotecan (as the free base), 60 mg of mannitol, 25 mg of tartaric
acid and 2 M hydrochloric acid and/or 0.05 M sodium hydroxide
for pH adjustment to 3.0. The content of each vial was reconsti-
tuted with 2 ml of sterile water for injection, USP, yielding a
2.5 mg ml-1 solution of topotecan. The appropriate dosage of the
drug was diluted in 50 or 100 ml of0.9% sodium chloride and was
administered intravenously over 30 min by a syringe pump.
Etoposide capsules were manufactured at the hospital's phar-
macy (Jonkman-de Vries et al, 1996). Etoposide was synthesized
by Omnichem and obtained from Pharmachemie (Haarlem, The
Netherlands). The capsule was a hard gelatin capsule (no. 3;
Spruyt-Hillen, Utrecht, The Netherlands), which contained 20 mg
of etoposide and 60 mg of microcrystalline cellulose (Avicel,
Brocacef, Maarssen, The Netherlands).
The starting doses of topotecan and etoposide were 0.5 mg m-2
on days 1-5 and 20 mg twice daily on days 6-12 respectively. The
regimen was intended to be repeated every 4 weeks. This could be
changed during the study to either shorter or longer intervals
depending on bone marrow recovery. Doses were escalated in an
alternating way according to the scheme in Table 1. Upon identifi-
cation ofthe MTD, the study was designed to reduce the topotecan
dose by one level and prolong etoposide dosing to 10 days.
Treatment cycles were to be repeated at 3-week intervals. Patients
were scheduled to receive at least two courses. No dose escalation
was permitted in individual patients. Patients with progressive
disease were removed from the study.
Patient evaluation
Pretreatment evaluation included a complete medical history and
complete physical examination. Before each course, chemistry
and haematology profiles, creatinine clearance and urine were
checked, as were chest radiographs and electrocardiograms.
Haematology was checked twice weekly. Weekly evaluations
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included serum chemistry screen and urinalysis. Tumour measure-
ments were performed every other cycle. All toxicities observed
were graded according to the common toxicity criteria (CTC). The
dose-limiting toxicity was defined as (a) grade IV neutropenia or
thrombocytopenia for more than 7 days or neutropenic fever
requiring hospitalization and i.v. antibiotics, (b) the impossibility
to re-treat apatient according to schedule, or (c) othergrade III-IV
toxicities with the exception ofalopecia, nausea and vomiting. The
MTD was defined as the highest dose that can be safely adminis-
tered to a patient producing tolerable, manageable and reversible
toxicity of CTC grade III in at least two out of a maximum of six
patients.
Pharmacokinetic studies
Clinical pharmacokinetic studies of topotecan and etoposide were
performed in at least two patients per dose level. On day 1, blood
samples (5 ml each), taken from an in-dwelling intravenous cannula
placed in the arm contralateral to the arm receiving topotecan, were
collected in heparinized tubes at 11 time points: preinfusion at 5, 15
and 30 min during the infusion, and at 15 and 30 min and 1, 2, 3, 4,
and 6 h after stopping the infusion. On day 6, patients received the
moming dose (one ortwocapsules) ofetoposide, andbloodsamples
were taken before dosing and at 15, 30 and 45 min, and 1, 1.5, 2, 3,
4, 8, 12 and24 h afteringestion. Additional etoposideblood samples
were taken on day 12 during the first and subsequent courses to
assess steady-state concentrations and possible accumulation.
Plasma was obtained by immediate centrifugation of the samples
(5 min; 3000 r.p.m.) and stored at -30°C until analysis. Urine was
collected as 24-h aliquots from the start ofinfusion on days 1-5 and
samples were frozen until analysis.
Table 2 Patient characteristics
Number of Response
patients
PR SD PD NA
Number of patients 30
Male/female 11/19
Median age (range) 54 (32-73)
Performance status
0 15
1 10
2 5
Prior therapy
None 3
Chemotherapy 21
Radiotherapy 0
Chemotherapy and radiotherapy 6
Tumour sites
Ovary 14 1 6 4 3
Colorectal 7 3 3 1
Lung (SCLC) 2 1 1
Gall bladder 1 1
Stomach 1 1
Pancreas 1 1
Sarcoma 1 1
Head/neck 1 1
Fallopian tube 1 1
Unknown origin 1 1
Abbreviations: SCLC, small-cell lung cancer; PR, partial response; SD, stable
disease; PD, progressive disease; NA, not assessable
Plasma levels of total topotecan (lactone plus carboxylate form)
weredeterminedby avalidatedhigh-performance liquidchromatog-
raphy (HPLC) method as developed in our laboratory (Rosing et al,
1995). Urine was diluted (1:50) with methanol, acidified with
perchloric acid2% (1:1) to apHof1.0, anddirectly injected ontothe
HPLC column. Plasma levels of etoposide were determined by
HPLC using a modification of the method by Sinkule and Evans
(1984). To 500 ,l ofplasma, 2 ml of 1,2-dichloro ethane and 100gl
of a 15 nmol ml-1 stock solution of teniposide (used as an internal
standard) were added. The sample was vortex-mixed for 10 s and
then centrifuged for 10 min at 3000 r.p.m. The plasma layer was
removed and the organic layer was evaporated under a nitrogen
stream. The residue was reconstituted with 200 ,l of 0.01 M phos-
phate buffer solution pH 6.5/acetonitrile (1:1, v/v) and aliquots of
50 ,l were injected onto the HPLC column. Separation of the
sample was accomplished by reverse-phase HPLC, using a Model
SP8875 autosampler [Thermo Separation Products (TSP), Fremont,
CA, USA], a Model 510 solvent delivery system (Waters Assoc.,
Milford, MA, USA), equipped with a ,u-Bondapakphenyl analytical
column (300 mmx 3.9 mmi.d.; particle size 10jum; WatersAssoc.).
The mobile phase consisted of water-acetonitrile-acetic acid
(690:300:10, v/v/v). The flow rate was 1.0 ml min-m and analyses
wereperformed atambienttemperature. Detection wasperformed at
281 nm using a Model Spectra 200 programmable wavelength
detector (TSP). Quantitative computations were based on the ratio
ofthe peak areas ofetoposide and teniposide.
For either drug, the maximum plasma concentration after a
single dose (Cmax), the time to reach the maximum concentration
(T ax) and the lag-time (tlag) were determined graphically. The
AUC was determined using the linear logarithmic trapezoidal
method with extrapolation to infinity. Total body clearance from
plasma (CL), apparent volume ofdistribution at steady-state (VS1),
elimination rate constant (k), elimination half-life (t,, 1), and
maximal and minimal steady-state concentrations (Cmaxss and
Cmons)of etoposide were calculated using standard equations
(Rowland and Tozer, 1989).
Relationships between systemic exposure to either drug and
pharmacodynamics, in particular the dose-limiting toxicities, were
explored using scatter plots of the dose or pharmacokinetic para-
meters vs the percentage decrease in WBC, absolute neutrophil
count (ANC) and platelets. The percentage decrease is defined as:
% decrease = Pretreatment value - value ofthe nadir
Pretreatment value x 100%
The data were fitted using a sigmoidal maximum effect (Emax)
model, as described by the modified Hill equation (Holford and
Sheiner, 1982):
E = (Emax)(DE)Y
(DE50)y + (DE)r
where E represents the observed effect (i.e. % decrease) observed
at drug exposure DE, Emax denotes the maximal elicitable effect,
which is fixed at 100 (i.e. 100% decrease) for cytotoxicity. DE is a
measure ofdrug exposure (i.e. AUC, Cmax, time above a threshold
concentration of 10 nmol 1-1 (t > 10 nmol 1-1)), DE50 represents the
drug exposure associated with 50% ofEmax and yis the Hill coeffi-
cient, which describes the sigmoidity of the curve. Statistical
analysis was performed with the Number Cruncher Statistical
System (NCSS, Kaysville, UH, USA, 1992). Data are presented as
means ± s.d.
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Table 3 Haematological toxicity
Dose Number of Number of Neutropenia Thrombocytopenia Anaemia
level patients courses
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
1 3 22 0/0* 0/0 0/0 0/0 0/2 0/1
2 4 16 2/4 0/1 2/4 0/0 0/2 0/0
3 3 12 1/3 0/1 0/0 0/0 0/0 0/0
4 6 20 4/6 3/6 1/1 1/1 0/1 1/1
3a 7 34 1/6 3/13 2/5 0/0 2/3 0/0
2a 6 27 3/12 2/4 1/3 0/0 0/0 0/0
*Number of patients developing toxicity in the first course/number of courses causing toxicity for all courses.
Table 4 Nadir blood counts
Dose Patients Courses ANC (x 1091-') Platelets (x 1091-') Haemoglobin (g dl-')
level
First course All courses First course All courses First course All courses
1 3 22 3.1 (1.4-3.4) 2.0 (1.4-5.2) 264 (203-344) 211 (140-366) 6.6 (5.8-8.1) 5.9 (3.1-8.1)
2 4 16 1.0 (0.5-1.3) 1.1 (0.5-3.0) 58(33-82) 66(30-120) 5.8 (5.0-7.5) 6.1 (4.7-7.5)
3 3 12 1.0 (0.5-1.5) 1.2 (0.4-2.2) 104 (97-195) 175 (91-250) 6.3 (5.9-6.9) 5.7 (5.0-6.9)
4 6 20 0.3 (0.0-0.8) 0.7 (0.0-2.0) 107 (8-187) 164(8-217) 5.5 (4.1-7.4) 6.8 (4.1-7.4)
3a 7 34 0.8 (0.1-1.3) 0.8 (0.1-3.2) 107(31-268) 86(30-378) 6.1 (4.4-7.8) 5.9 (4.4-7.8)
2a 6 27 0.7 (0.4-1.0) 0.8 (0.4-1.6) 68 (31-264) 202 (31-323) 6.5 (4.9-7.5) 6.2 (4.9-7.5)
Numbers in parentheses show range of nadir values.
RESULTS
A total of30 patients was registered onto this trial. Eleven patients
were men and 19 were women, with a median age of 54 years
(range, 32-73). Twenty-five patients (83%) had a performance
status of either 0 or 1. Diagnoses included a predominance of
ovarian and colon cancers. All but three patients had received
previous cytotoxic therapies. Thirteen and fourteen patients
received one and two or more (median 3, range 2-4) previous
chemotherapeutic regimens respectively. Additional patient char-
acteristics are outlined in Table 2. A total of 131 full courses was
administered, with a median number of four (range, 1-10) per
patient. Four patients received only one course. In two patients,
this was because of rapid progressive disease. One patient had a
rapid deterioration in performance status immediately after
registration onto the study and went off-study because of poor
condition and unacceptable pre-existing vomiting. One patient
developed grade IV neutropenia with fever, most probably atyp-
ical pneumonia, with negative blood cultures and fever persisting
while on antibiotics. Of all courses administered at dose levels
1-4, two courses (4%) had to be postponed for 1 week because
of unresolved neutropenia and fever, and a treatment delay of
2 weeks was required in one course because of an abscess and
rapidly increasing ascitic fluid production. With the adjusted 3-
week schedule (dose levels 2a and 3a, Table 1), only 56% of all
treatment courses could be given at theplanned interval because of
unrecovered bone marrow. However, most patients (88%) could be
re-treated by day 28. No intrapatient dose reductions orescalations
were made.
Twenty-nine patients were assessable for toxicity during the
first course. One patient was not evaluable because she received
only topotecan. Her first course was abrogated because of rapid
worsening of her performance status after registration onto the
trial. Myelosuppression, primarily neutropenia, was the dose-
limiting toxicity forthe combination oftopotecan and etoposide in
this schedule (Table 3). Cohorts ofthree patients were entered and
doses were escalated to topotecan 1.25 mg m-2 and etoposide
40 mg twice daily (dose level 4). At this dose level DLT occurred
in two out of six patients. One patient experienced grade IV
neutropenia and grade III mucositis, another patient developed
grade IV neutropenia with neutropenic fever. Both patients were
heavily pretreated. The first patient had received three previous
regimens for the treatment of metastasized SCLC, the second
patient was an ovarian cancer patient who had received four
previous regimens, including platinum-based therapy. To investi-
gate furtherdose intensification, additional patients were treated at
3-week intervals with the topotecan dose reduced by one level to
1.0 mg m-2, but with etoposide administration prolonged from 7 to
10 days. A time delay to retreatment emerged as DLT. In three out
of seven patients, treatment was postponed for one week because
of unrecovered bone marrow. One patient developed neutropenic
fever. The etoposide dose was then reduced by one level to 20 mg
twice daily. At this dose level, three out of six patients developed
DLT. Two patients had treatment delays of one week because of
unresolved neutropenia. One patient experienced grade III neuro-
logical toxicity, being motor function loss of the right hand.
Pathology was non-diagnostic. Further attempts to dose intensifi-
cation were not performed and the study was closed.
Haematological toxicity
The principal toxicity was myelosuppression, primarily
neutropenia. Table 4 lists the median and range ofnadir haemato-
logical toxicity at each dose level during the first course and all
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Figure 1 Representative plasma concentration vs time curves of
topotecan as the sum of the lactone and carboxylate forms (-) and
N-desmethyltopotecan (----) after a 30-mmn intravenous infusion of topotecan
0.5mg m2 2(0), 1.0mg in-2 (A) and 1.25mg in-2 (0). The arrow indicates the
end of infusion
courses. The neutrophil nadir occurred on day 16 (range 9-24) for
the initial courses, and on day 13 (range 8-24) for all courses. In
the first course, the median duration of neutropenia was 9 days
(range 3-17), with recovery to grade I on day 24 (range 16-29). At
the first dose level, no grade III or IV haematological toxicity
occurred. At the second dose level, fourepisodes ofbriefgrade III
neutropenia and one episode ofgrade IV neutropenia were experi-
enced by two patients, including one heavily pretreated patient. At
the third dose level, grade III and IV neutropenia occurred in 25%
and 8% of courses respectively. At the fourth dose level, a higher
proportion of courses was associated with grade IV neutropenia.
Bothgrade III andIV neutropenia developed in 30% ofall courses.
When the protocol was amended to 10 days' etoposide administra-
tion in an effort to obtain higher dose intensity, relatively more
patients experienced grade IV neutropenia. Atdoselevel 3a, which
is identical to dose level 3 except for the length of etoposide
administration (10 and 7 days respectively), grade Ill and IV
neutropenia was noted in 12% and 56% of courses respectively.
The evaluation of nadir neutrophil and platelet counts in patients
who received two or more courses showed no evidence ofcumula-
tive haematological toxicity.
Thrombocytopenia occurred less frequently than neutropenia,
with only one episode of grade IV thrombocytopenia occurring in
a patient at the fourth dose level, whereas 25, 5, 15 and 11% of
courses at dose level 2, 4, 3a and 2a respectively, were associated
with grade III thrombocytopenia. All but three patients experi-
enced anaemia, which was severe (grade III and IV) in ten courses
(8%), requiring the transfusion of a total of 72 U of packed red
blood cells (RBCs) during 26 courses involving 14 patients.
Non-haematological toxicities
Non-haematological drug toxicities were relatively mild. Transient
grade I andII nauseaandvomitingoccurredin 38 and 19% ofassess-
able courses, respectively, and could generally be controlled by
standard antiemetics. Other grade I or II gastrointestinal side-effects
Table 5 Pharmacokinetic parameters of total (lactone plus carboxylate) topotecan following a 30-min infusion
Dose Number of Cm AUCo CL V, t12,
(mg m-2 patients (nmol 1-') (h nmol-' I-') (I h-' m-2) (I m-2) (h)
0.5 3 48.9± 4.3 80.3 ± 10.2 14.9 ± 1.8 34.0 ± 2.6 1.9± 0.1
1.0 18 81.9±21.6 184.6±38.1 13.4±2.6 36.4±5.2 2.2±0.3
1.25 3 104.8 ± 8.3 199.8 ± 51.2 15.6 ± 4.0 33.7 ± 6.7 1.8± 0.1
Abbreviations: see Materials and methods section.
Table 6 Pharmacokinetic parameters of N-desmethyltopotecan after a 30-min infusion of topotecan
Dose Number of Cmax AUC(40,.5 h) AUC(O t.x
; (mg m-2) patients (nmol 1-') (h nmol-' 1-1) ratio (%) (h) (h)
0.5 3 0.23±0.10 1.04±0.43 1.3±0.6 4.2±0.6 0.7±0.2
1.0 18 0.43± 0.21 2.05 ± 1.09 1.1 ± 0.5 3.4± 1.1 0.6 ± 0.2
1.25 3 0.53 ± 0.34 2.60 ± 1.74 1.4 ± 0.9 2.9 ± 0.5 0.6 ± 0.4
Abbreviations: see Materials and methods section;AUC(t)O,65 h' area under the plasma concentration vs time
curve up to last measured point; AUC(t) ratio, metabolite-to-topotecan AUC(O ratio.
Table 7 Pharmacokinetic parameters of etoposide after oral administration
Dose Number of Cmax tx AUCO+. tV20 C.x3 Cmin,
(mg) patients (lmol 1-') (h) (h,mol-' I-i) (h) (imol j-t) (1tmol 1-')
20 7 0.75±0.54 2.4±1.2 5.39±2.88 4.8±2.5 1.02±0.49 0.17±0.15
40 8 1.23 ± 0.57 2.3± 1.0 12.97 ± 8.51 7.8 ± 5.3 1.82 ± 0.83 0.61 ± 0.65
Abbreviations: see Materials and methods section.
British Journal ofCancer (1997) 76(11), 1500-1508 0 CancerResearchCampaign 1997Phase Istudyofsequential topotecan andetoposide 1505
Figure 2 The percentage decrease in ANC vs topotecan AUC dunng
course 1 (, -). The curve is fitted to a sigmoidal E,. model (parameters:
AUC 0 =79.2hnmol-1 1i1; y
= 2.1). These data are superimposed on the
sigmoidal model derived from a preceding single-agent phase I tral (El,
AUCG5 =79.2 hnmol- li-i; y
= 1.8) (Van Warmerdam et al, 1995)
included mucositis (I11% of courses; six patients), being severe
(grade III) in one patient at the fourth dose level, diarrhoea (17%
of courses; 11 patients), obstipation (15% of courses; eight
patients), and mouth dryness (7% of courses; three patients).
Alopecia was observed in 19 patients, and was complete in five
patients. Six patients experienced neurotoxicity during 18 courses
(14%) at all dose levels, being severe (grade III) in one patient at
dose level 2a, who experienced motor function loss of the right
hand for several days during his first course. Neurotoxicity
primarily manifested in tingling hands and toes and was pre-
existing in three patients who had been previously treated with
platinum-based regimens. One ovarian cancer patient at dose level
2a had grade I cystitis for 10 days, which was possibly drug-
related. Four patients (5% of courses) developed microscopic
haematuria (grade I) and eight patients (15% of courses) had mild
proteinuria. The most common complaint was fatigue (35% of
courses). All toxicities were reversible and not dose-related.
Pharmacokinetics
Twenty-four patients underwent pharmacokinetic monitoring on
day oftopotecan administration of the first course. Fifteen patients
also had blood samples taken with their first dose of etoposide (day
6). Representative plasma concentration vs time curves of total
topotecan are shown in Figure 1. Mea topotecan Cd and AUC
increased linearly with dose in the dose range used, but there was
considerable overlap in individual values between different dose
levels. Individual elimination curves of topotecan were well
described using conventional compartmental modelling. A two-
compartment model provided the best fit to the data, based on visual
inspection and Akaike's information criteria (AIC). Post-infusion
plasma levels declined in a biphasic manner with mean alpha and
beta half-lives of 3.8 ± 3.2 min and 2.1 ± 0.3 h respectively. The
systemic clearance rate for topotecan was 13.8 ± 2.7 1 hsin-2 and
the steady-state volume of distribution was 36.7 ± 6.2c 1 mota
Phaomacokinetic parameters are presented in Table 5. Twvo patients
at the 1.0 mg md level had ascitic fluid analysed for topotecan.
Ascitic fluid concentrations of 9.51 and 11.63 nmol1'g were
obtained at approximately 2 h after infusion, with ascitic fluid-to-
plasma ratios of 0.54 and 0.52. Topotecan 24-h urinary excretion
data over 5 days were available for 27 patients. The percentage
of the administered dose recovered in the urine was 41 ± 10%
(range 25-71).
During HPLC analysis ofplasma and urine samples, an uniden-
tified peak eluting just after topotecan was observed in the
chromatograms, which was not present in blank and calibration
samples. The compound was isolated from urine and identified to
be as theN-desmethyl derivative oftopotecan (Rosing et al, 1997).
Under our assay conditions topotecan and N-desmethyltopotecan
had equivalent extraction ratios and fluorescence yields that
permitted metabolite levels to be quantified using the topotecan
calibration curve. Desmethyltopotecan appeared in plasma after
cessation of the 30-min topotecan infusion, with a lag-time of
0.58 ± 0.24 h. Maximal metabolite plasma concentrations of
0.23 + 0.10, 0.43 ± 0.21 and 0.53 ± 0.34 nmol 1- were obtained
after respective topotecan doses of 0.5, 1.0 and 1.25 mg m-2
(Figure 1 and Table 6). The time to reach maximal plasma levels
was 3.4 ± 1.0 h. The metabolite-to-topotecan ratio of maximal
plasma levels was 0.5%. At the last measured time point (6 h post-
infusion) desmethyltopotecan plasma levels were still at or near
the maximal concentration. The AUC(t) was calculated up to this
last measured time point. The metabolite-to-topotecan AUC(t)
ratio was 0.012. Plasma levels of desmethyltopotecan at 2 h after
infusion on days 2 to 5 were significantly higher than on day 1,
ranging from 42 ± 26% higher on day 2 to 53 ± 41% on day 5,
which suggests accumulation of this species. The 24-h urinary
recovery of desmethyltopotecan was 1.4 ± 0.6% of the adminis-
tered topotecan dose. In four patients, urine was collected for 48 h
after the fifth daily topotecan infusion. An additional 0.4% was
excreted in the urine as the metabolite from 24 to 48 hours after
infusion.
Etoposide pharmacokinetics were described using non-compart-
mental modellingtechniques. Maximumplasmalevelsof0.75± 0.54
and 1.23 ± 0.57,mol 1-1 were reached at 2.4 ± 1.2 and 2.3 ± 1.0 h
after ingestion of respective etoposide single doses of 20mg and
40 mg (Table 7). The maximum steady-state plasma concentrations
were calculated as 1.02± 0.49 and 1.82±0.83 gmol1-' afterdoses of
20 and40mg twicedailyrespectively. Theplateautroughconcentra-
tions were calculated as 0.17 ± 0.15 and0.61 ± 0.65 jmol 1-1 respec-
tively. No drug accumulation could be detected from repetitive
determination of steady-state etoposide concentrations during the
firstand subsequent courses. The meanplasmaconcentrations atday
12 ofall courses were 0.71 ± 0.56jmol 1-' (n = 8) after 20mg twice
daily, and 1.78 ± 0.61 jmol 1-1 (n = 24) after 40 mg twice daily,
which are within the range of calculated maximal and minimal
steady-state levels.
Pharmacodynamics
The relationships between topotecan pharmacokinetic parameters
(i.e. AUC, t > 10 nmol 1-', Cm.) or dose and myelosuppression
during the first course could be adequately described by a
sigmoidalEmax model. Topotecan AUC was most predictive ofthe
percentage of decrease in WBC (r2 = 0.70) and ANC (r2 = 0.65).
Interestingly, the latter relationship could be superimposed on the
model derived from a preceding phase I trial of single-agent
topotecan (Van Warmerdam etal, 1995). A plotofthis relationship
is depicted in Figure 2. T> 10 nmol 1-l and dose also correlated
well with the percentage of decrease in neutrophils (r2 = 0.60 in
both cases). With this model, the dose associated with a 50%
decrease in ANC (D50) was 0.6 mg m-2 day-1. In all cases, the
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sigmoidal model produced better fits compared with linear equa-
tions. Desmethyltopotecan AUC(t) was not related to myelosup-
pression. In addition, exploring correlations between etoposide
pharmacokinetics (i.e. AUC, Cm,.) or total dose and haematolog-
ical toxicity did not yield any significant relationship.
Responses
Twenty-four patients were assessable for therapeutic efficacy. A
partial response occurred in a 55-year-old woman with ovarian
cancer. Her response was documented after four courses of
topotecan 1.0 mg m-2 day-1 for 5 days and etoposide 40 mg twice
daily for 10 days (dose level 3a) and was brief (3 months). Sixteen
patients (64%) had stable disease for at least 4 months (range
4-10+). Four ovarian cancer patients had significantly decreased
tumour markers (CA-125) to normal values, but remained stable.
DISCUSSION
Preclinical studies have demonstrated mixed results when topoiso-
merase I and II inhibitors were combined. The reason for the
discrepancies in cytotoxic effects of the combination might relate
to the scheduling of both kinds of inhibitors, the cancer cell lines
and the camptothecin analogue used. Additive and synergistic
effects were observed for simultaneous exposure to etoposide and
CPT-l 1 on acute lymphoblastic leukaemia cells and human lung
cancer cell lines (Kano et al, 1992; Takada et al, 1992) Contrary to
these results, simultaneous treatment of hamster lung fibroblasts
(D'Arpa et al, 1990), human leukaemia cells (Kaufmann, 1991),
human colon carcinoma cells (Bertrand et al, 1992), and human
tumour xenografts (Kim et al, 1992) with camptothecin analogues
and etoposide or doxorubicin attenuated the cytotoxicity of these
agents over single-agent exposure. Sequential administration of
camptothecins and etoposide was shown to circumvent the antago-
nistic cytotoxicity (Bertrand et al, 1992; Chang et al, 1992; Cheng
et al, 1994). Bertrand et al (1992) reported additive enhancement
of cytotoxicity in human colon carcinoma cells, provided camp-
tothecin and etoposide were administered 6-8 h apart. The addi-
tive effect did not depend on the order ofadministration. However,
several authors emphasized a sequence dependency in the cyto-
toxic effect. Kozelsky et al (1995) showed maximum synergy in
hamster lung fibroblast cells with etoposide administration after
topotecan exposure compared with the opposite sequence.
Masumoto et al (1995) demonstrated that significant synergy
occurred only when etoposide was given after a 48-h drug-free
interval after treatment with SN-38, the active metabolite of CPT-
11, whereas cytotoxicity was slightly reduced when etoposide was
administered concurrently with or immediately after SN-38. CPT-
11 pretreatment was shown to enhance the cytotoxicity of doxo-
rubicin by increasing topoisomerase-II mRNA expression and the
S-phase cell population 24 and 48 h after CPT-l 1 treatment,
respectively, in the case of oesophageal and colon tumour
xenografts (Kim et al, 1992).
We performed a dose-finding study of topotecan combined with
etoposide in a sequential fashion. A suitable dose for use in phase
II clinical trials is topotecan 1.0 mg m-2 on days 1-5 and etoposide
40 mg twice daily on days 6-12 every 4 weeks. Neutropenia was
the principal dose-limiting toxicity of this combination. The rela-
tive low dose intensity of etoposide at the recommended dosage
(Table 1) led us to focus on extended etoposide dosing from 7 to 10
days. Concurrently, we attempted to reduce the drug-free interval,
as stabilization of the topoisomerase enzyme-DNA complex by
topoisomerase inhibitors is a readily reversible process. With the
removal ofthe drug, enzyme activity is restored and DNA damage
repaired. However, dose intensification with treatment at a 3-week
cycle and protracted etoposide administration was not feasible.
With this adjusted schedule, only 56% of all treatment courses
could be given at the planned 3-week interval because of unrecov-
ered bone marrow, but most patients (88%) could be re-treated by
day 28. The definition of DLT in this protocol (time delay to
retreatment) results in our recommendation of dose level 3 for
phase II trials. However, based on observed complete recovery
from neutropenia on day 28 and the absence of cumulative myelo-
toxicity, treatment at doses of topotecan 1.0mg m-2 on days 1-5
and etoposide 40 mg twice daily on days 6-15 (dose level 3a)
should be possible in 4-week cycles to obtain a higher dose inten-
sity. At these doses, 68% of courses was associated with grade III
or IV neutropenia. A comparison of the current study with single-
agent phase I studies shows that topotecan in combination with
prolonged low-dose oral etoposide could only be given at 67-83%
ofthe single-agent dosage. Rowinsky et al (1991) and Verweij et al
(1993) recommended a dose of 1.5 mg m-2 day-' for single-agent
topotecan in the 30-min daily times five infusion schedule
repeated every 3 weeks for both minimally and heavily pretreated
patients. At this dose, approximately 75% of courses resulted in
grades III or IV leucocytopenia and neutropenia (Rowinsky et al,
1991; Verweij et al, 1993). Saltz et al (1993) recommended
doses of 1.5 and 1.25 mg m-2 daily in previously untreated and
previously treated patients respectively. This indicates that bone
marrow suppression of the combination is more severe compared
with topotecan administered singly. Similar results have been
reported previously. A combination regimen oftopotecan adminis-
tered as a 72-h infusion followed by bolus doxorubicin on day 5
resulted in unexpected severe neutropenia at the first dose level
(topotecan/doxorubicin 0.35/45 mg m-2 day-') (Tolcher et al,
1994). Further dose escalation was performed with G-CSF
support. Another study investigated a 72-h continuous infusion of
topotecan, dose range 0.17-1.05 mg m-2 followed by etoposide
100 mg m-2 given over 2 h on days 7, 8 and 9 (Eckardt et al, 1993)
Haematological toxicities were more severe than expected from
singly administered topotecan and etoposide, which was suggested
to represent a synergistic effect ofthe combination. Topoisomerase
II levels were found to be markedly increased immediately before
etoposide administration on day 7, and were decreased on day 9
(Eckardt et al, 1994).
In the current trial, the sequential combination of topotecan and
etoposide induced minimal platelet count depression, with grade III
to IV thrombocytopenia occurring in 11% of all courses. Anaemia
requiring RBC transfusions occurred in 20% of all courses
involving 14 patients. More modest anaemia was noted in most
courses. The incidence of non-haematological adverse effects was
typical for topotecan. Mild to moderate nausea and fatigue were
most troublesome. Reversible neurotoxicity occurred in six
patients, being severe (grade III) in one patient atdose level 2a, and
was thought to be platinum-related in three patients. Neurotoxicity
has not been noted frequently with either topotecan or etoposide.
One patient developed mild cystitis (grade I) during her seventh
course. Haemorrhagic cystitis was a major toxicity encountered
with sodium camptothecin, but has not been observed with
topotecan (Rowinsky et al, 1991; Verweij et al, 1993). Except for
incidental findings ofmildproteinuria and microscopic haematuria,
no other episodes ofrenal toxicity were observed in this study.
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Topotecan pharmacokinetic parameters were similar to those
reported in previous pharmacokinetic studies (Herben et al, 1996).
The current study has used total (lactone plus carboxylate form)
topotecan levels in determining drug exposure. The lactone form
of topotecan, which is the active cytotoxic form, is quite labile
and undergoes a rapid pH-dependent reversible hydrolysis to a
carboxylated open-ring form under physiological conditions.
Although the carboxylate form lacks topoisomerase inhibiting
activity, the potential for conversion to the lactone suggests that
cytotoxic activity should bepossibleregardless ofwhatproportion
of topotecan is in the open-ring form in the extracellular space.
Previous studies have demonstrated that total topotecan AUC and
Cmax values were equally, or even better, related to haematological
toxicity compared with lactone AUC or Cma. This finding has
led several authors to question the need for all efforts to
quantitate lactone levels separately (Grochow et al, 1992;
Stewart et al, 1994).
This is the first study reporting the pharmacokinetics of a
metabolite of topotecan. During HPLC analysis of topotecan
plasma and urine samples, we became aware of an unidentified
peak eluting just after topotecan that was not present in preinfu-
sion samples. The potential metabolite was isolated from urine
samples (Rosing et al, 1997). Mass spectrometry data, along with
HPLC retention and fluorescence data, demonstrated that this
compound was identical to a synthetic reference standard N-
desmethyltopotecan (SB 209780) (Boehm et al, 1991). Like
topotecan, the desmethyl derivative possesses alactone ring that is
reversibly hydrolysed to an open carboxylate form (Rosing et al,
1997); it has slightly less anti-tumour activity compared with the
parent compound (Johnson and Wood, personal communication).
The metabolite appeared in plasma after cessation of the 30-min
topotecan infusion. Maximal plasma levels were reached at
approximately 3 h after infusion. Desmethyltopotecan was found
to accumulate during 5 consecutive days of treatment. In view of
the relative low amounts found in plasma, the clinical importance
ofthe metabolite seems limited.
Etoposide pharmacokinetic parameters were similar to those
reported in a preceding bioavailability study of the etoposide
capsules used in the current trial (Jonkman-de Vries et al, 1996).
This indicates that topotecan does not interfere with etoposide
pharmacokinetics. In view of extrapolation of the results of this
trial to future studies, it is important to mention that the bioavail-
ability of the etoposide capsules used in this study was approxi-
mately 34%, which is lower than the normal value ofaround 70%
of the commercially available etoposide capsules (Vepesid;
50 mg). In addition, it appeared that the home-made capsules
acted, to some extent, as slow-release devices. The terminal half-
life of the drug was significantly higher after oral than after intra-
venous administration (Jonkman-de Vries et al, 1996).
The severity of neutropenia was more closely related to the
AUC oftopotecan than to the AUC ofits metabolite or etoposide.
Patients who received equal topotecan doses but different dose
intensities to etoposide, show the same sigmoidal relationship
between topotecan dose or AUC and the percentage ofdecrease in
ANC. The obtained model superimposed on the sigmoidal curve
fit found in the phase I study of a daily times five infusion
schedule oftopotecan alone. Itthus appears that in this schemathe
percentage decrease in ANC is primarily dependent on systemic
exposure to topotecan. Nonetheless, a correlation coefficient of
0.81 (r2 = 0.65) illustrates that the pharmacokinetic variability of
topotecan is not the only determinant ofthis toxicity.
Conclusive evidence on the contribution of etoposide to the
myelotoxicity is lacking. Etoposide-induced toxicity has been
shown to be dose and schedule dependent. Prolonged exposure to
plasma etoposide concentrations of around 1.7 ,umol 1-l has been
advocated to be optimal for anti-tumour activity (Slevin et al,
1989; Thompson et al, 1993), whereas peakplasma concentrations
above 17 gmol [-1 are associated with significant toxicity (Clark et
al, 1989). The maximal plasma concentrations obtained in this
study are apparently below the threshold concentration needed to
cause a marked decrease in neutrophils. This hypothesis is
evidenced by results from the bioavailability study of the etopo-
side capsules used in this study, in which no episodes of
neutropenia were observed among a total of 14 patients receiving
20 mg twice daily for prolonged periods (range 7-21 days)
(Jonkman-de Vries et al, 1996).
In summary, topotecan and etoposide given in combination
could not be administered at their individual MTDs. With combi-
nations of myelosuppressive agents, it is difficult to determine
whether the observed myelotoxic effect is significantly higher, i.e
synergistic, or not statistically different, i.e. additive, compared
with the effect that could theoretically be expected (Merlin et al,
1994). Modelling the toxic effects of a two-drug combination
requires the relationship between pharmacokinetics and pharma-
codynamics of each individual agent to be known. In this study,
only the relationship between topotecan pharmacokinetics and
resulting toxicity is known. The observed haematological toxicity,
measured by the percentage decrease in neutrophil count, is not
significantly different from the expected toxicity of topotecan
given alone at the same dosage based on the previously
documented concentration-effect relationship of topotecan. This
implies thatthe sequential combination oftopotecan and etoposide
most likely results in additive, rather than synergistic myelosup-
pressive interaction. In view of the anti-tumour activity of this
combination, only one brief partial response was observed in an
ovarian cancer patient, whereas 64% of evaluable patients had
stable disease. Phase II trials will be needed to establish thebenefit
ofthis combination over single-agent administration.
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